8-K: Helius Medical Technologies Announces 1-for-15 Reverse Stock Split to Regain Nasdaq Compliance

Helius Medical Technologies will implement a 1-for-15 reverse stock split, effective May 1, 2025, to meet Nasdaq's continued listing requirements.

Summary

• Helius Medical Technologies has announced a 1-for-15 reverse stock split of its Class A common stock.
• The reverse stock split will be effective at 5:00 p.m. Eastern Time on May 1, 2025.
• Trading on a split-adjusted basis will begin on the Nasdaq Capital Market on May 2, 2025.
• The reverse stock split was approved by stockholders at the annual meeting on April 21, 2025.
• The primary reason for the reverse stock split is to comply with Nasdaq's continued listing requirements.
• Every 15 shares of common stock will be combined into one share.
• The par value per share will remain at $0.001, and the number of authorized shares will stay at 150 million.
• The number of outstanding shares will decrease from approximately 7.9 million to approximately 0.5 million.
• Stock options and warrants will be adjusted proportionally.
• Fractional shares will be rounded down, and stockholders will receive cash equal to the market value of the fractional share.
• The new CUSIP number for the common stock is 42328V 884.
• Equiniti Trust Company, LLC will act as the exchange agent for the Reverse Stock Split.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is taking action to maintain its listing, reverse stock splits are often perceived negatively by investors.

Positives

• The reverse stock split is intended to help Helius Medical Technologies maintain its listing on the Nasdaq Capital Market.
• The company has engaged Equiniti Trust Company, LLC, a transfer agent, to manage the reverse stock split.

Negatives

• Reverse stock splits are often viewed negatively by investors as they can indicate financial distress or an attempt to artificially inflate the stock price to meet listing requirements.

Risks

• The reverse stock split may not be successful in maintaining Nasdaq listing compliance.
• The reverse stock split could negatively impact investor perception of the company.
• The company's stock price may continue to decline even after the reverse stock split.

Future Outlook

The company expects its common stock to begin trading on a split-adjusted basis on May 2, 2025, under the same ticker symbol HSDT.

Industry Context

Reverse stock splits are a relatively common mechanism for companies facing delisting from exchanges like Nasdaq. They are often used by companies in the biotechnology and pharmaceutical industries to maintain compliance while they work towards commercializing their products.

Comparison to Industry Standards

• Other companies in the biotechnology sector, such as XOMA Corporation and BioSpecifics Technologies Corp., have previously implemented reverse stock splits to maintain Nasdaq listing compliance.
• The 1-for-15 ratio is within the typical range for reverse stock splits, which can range from 1-for-2 to 1-for-30, as indicated in the document.

Stakeholder Impact

• Shareholders will have their existing shares combined into fewer shares.
• Shareholders may receive cash for fractional shares resulting from the reverse stock split.
• The reverse stock split is intended to benefit shareholders by helping the company maintain its Nasdaq listing.

Next Steps

• The reverse stock split will be implemented on May 1, 2025.
• The company's stock will begin trading on a split-adjusted basis on May 2, 2025.
• Equiniti Trust Company, LLC will manage the exchange of shares.

Key Dates

Keywords

reverse stock split, Helius Medical Technologies, HSDT, Nasdaq, listing compliance, common stock, stock split, neurotech